Cardiology
>
Prevention
—
Recent developments of interest in cardiovascular medicine
by
Nicole Lou, Senior Staff Writer, MedPage Today
August 27, 2024
FDA alerted to Inari Medical’s recall of instructions for use (IFU) of the ClotTriever XL catheter, 30 mm, following reports of injury and death due to entrapped devices or pulmonary emboli.
A 3-month physical activity intervention did not help sedentary adults reduce blood pressure, and may have even hurt pulse wave velocity. (Circulation)
Former director of FDA’s Center for Devices and Radiological Health failed to recuse himself from matters related to his wife’s law firm representing medical device manufacturers. (New York Times)
A Sacramento hospital is accused of not reporting a patient’s cardiac arrest death for almost a year and instead telling her family that she had discharged herself against medical advice. (The Times)
Amgen said it is offering free cholesterol tests in MinuteClinics at approximately 1,000 CVS Pharmacy stores nationwide.
A machine learning algorithm was developed to scour electronic medical records and flag people with a high probability of familial hypercholesterolemia. (JACC: Advances)
The cardiovascular benefits of semaglutide (Wegovy) applied to people with heart failure and obesity in the SELECT trial, regardless of ejection fraction. (The Lancet)
Medicare’s maximum annual costs for semaglutide are projected between $34 billion and $145 billion depending on how cardiovascular disease is defined for eligibility. (Annals of Internal Medicine)
FDA approved a labeling change so that people with a HeartMate 3 left ventricular assist device can eliminate aspirin from their medication regimen, Abbott said.
People who went on oral anticoagulation therapy after non-cardiac surgery showed no significant association between postoperative atrial fibrillation (Afib) and stroke. (Nature Medicine)
For the antithrombotic regimen of Afib patients after an acute coronary syndrome or percutaneous coronary intervention, it may be optimal to combine a P2Y12 inhibitor and apixaban (Eliquis) without aspirin. (Journal of the American College of Cardiology)
When Chinese traditional medicine was taken after radiofrequency catheter ablation for persistent Afib, a randomized trial found quality of life was improved and recurrent atrial tachyarrhythmias reduced. (European Heart Journal)
Patients with peripheral artery disease and intermittent claudication could walk more when low-dose rivaroxaban (Xarelto) was taken in addition to aspirin, according to results from a small trial. (NEJM Evidence)
Can naloxone (Narcan) be a treatment for cardiac arrests in general, opioid-related or not? (JAMA Network Open)
Arrhythmias arising from radiotherapy for non-small cell lung cancer could be linked back to radiation doses to specific cardiac substructures. (JACC: CardioOncology)
Nanox.AI said its upgraded artificial intelligence (AI) program, HealthCCSng V2.0, got FDA 510(k) clearance for measuring coronary artery calcium from routine CT scans.
Also cleared is the AI-powered AISAP CARDIO point-of-care ultrasound software platform for structural heart assessments, according to AISAP.
For patients with systemic light-chain amyloidosis, extracellular volume mapping was telling of cardiac involvement and long-term prognosis. (JAMA Cardiology)
A drug for multiple sclerosis may be repurposed to heal heart injuries, based on preclinical work. (Nature Cardiovascular Research)
Nicole Lou is a reporter for MedPage Today, where she covers cardiology news and other developments in medicine. Follow
Information contained on this page is provided by an independent third-party content provider. This website makes no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact editor @americanfork.business
